Abstract BACKGROUND: Oseltamivir and zanamivir have indication for treating symptomatic flu and in prophylaxis in epidemics for groups with high risk of complications. METHODS: Effectiveness data was identified in literature review, and costs were obtained from official systems and micro-costing. RESULTS: We adopted a decision-tree model to assess the effectiveness of chemoprophylaxis in Brazilian Unified Health System (SUS) perspective with willingness to pay BRL 30,000.00/QALY. The incremental cost-effectiveness ratio for chemoprophylaxis compared to no prophylaxis was -2,921.14/QALY. CONCLUSION: Chemoprophylaxis is cost-effective in Brazilian scenario.
Introduction
Oseltamivir and zanamivir are antiviral drugs recommended by World Health Organization (WHO) and Brazilian Health Ministry for chemoprophylaxis of influenza A (H1N1) for high risk groups (1,2). The analysis of complete evidence identified the risk of bias in favor of the technology (3) and the costeffectiveness was assessed in different countries but no analysis in Brazilian context was available.
Results and Discussion
We identified the effectiveness data in literature review. We assessed costs for the payer perspective in disease period and obtained data from official Brazilian Ministry of Health system and micro-costing at Unicamp University Hospital (study approved by Unicamp ethics committee, report 2.357.158/2017). Cost and effectiveness data is shown in Table. We adopted a decision-tree model ( Figure) and willingness to pay BRL 30,000.00/QALY (quality-adjusted life years). The incremental cost-effectiveness ratio (ICER) was calculated for prophylaxis compared to no prophylaxis. We tested the robustness of results using deterministic and probabilistic sensitivity analysis.
Figure. Decision-tree model
Calculated ICER as -2,921.14/QALY and -337.84 per H1N1 case avoided, with 43% probably of being of lower cost and higher effectiveness. 
Conclusions
Influenza A (H1N1) chemoprophylaxis is cost-effective in SUS perspective.
